# Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

> **NCT07486817** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer, Non-squamous, Non-small Cell

## Interventions

- **DRUG:** Zongertinib
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07486817
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-08
- **Primary completion:** 2027-08-12
- **Final completion:** 2029-08-25
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486817, "Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07486817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*